Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Advancing Patient Care in Hypertrophic Cardiomyopathy: Key Insights from the HFA 2024
Author(s): Ahmad Masri , Added: 1 year ago
Recorded during HFA 2024, Dr Caroline Coats, Glasgow University, UK, and Dr Ahmad Masri, Oregon Health and Science University, US, collaborate to explore the pivotal advancements in managing hypertrophic cardiomyopathy unveiled at the conference.This programme is thoughtfully divided into four chapters, facilitating a smooth journey through the latest HCM trial data, including a comprehensive… View more

Guidelines & Statements

Heart Failure
Arrhythmias and Sudden Death: What is New in HCM?
Author(s): Deepthi Rajan , Christopher Ryan Zörner , Morten Lock Hansen , et al Added: 1 month ago

Heart Failure

Prevention & Chronic Conditions
ACC 25: The MyPEAK-1 Study
Author(s): Milind Y Desai Added: 1 month ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene… View more

Heart Failure
HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in symptomatic nHCM
Author(s): Ahmad Masri Added: 2 years ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826). This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that… View more

Heart Failure
NHC On Demand Thumbnail
Author(s): Perry Elliott , Marianna Fontana , Ahmad Masri , et al Added: 2 months ago
Radcliffe Cardiologywas proud to hostNew Horizons in Cardiomyopathy 2025 (NHC), specially focused on cardiac amyloidosis and cardiomyopathy diagnosis and treatment.Day 1 focused on hypertrophic cardiomyopathy (HCM), with a detailed exploration of HCM and an emphasis on emerging therapies and management strategies. Day 2 focused on amyloidosis, providing a comprehensive update on the diagnosis and… View more

Heart Failure
Role of Imaging in Cardiomyopathies
Author(s): Vincenzo Castiglione , Alberto Aimo , Giancarlo Todiere , et al Added: 2 years ago

Imaging & Diagnostics

Heart Failure
Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy
Author(s): Long Peng , Tao Zeng , Enxi Quan , et al Added: 1 week ago

Cardiovascular Renal Metabolic

Heart Failure
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 3 days ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

Heart Failure

MI/ACS
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 5 days ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
AHA 23: Screening for Peripartum Cardiomyopathies Using an AI Enanced Digital Stethoscope
Author(s): Demilade Adedinsewo Added: 1 year ago
AHA 23 - We are joined by Dr Demilade Adedinsewo (Mayo Clinic, US) to discuss the findings from a study investigating the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population.In the intervention arm, the digital stethoscope correctly identified 92% of those with ejection fraction <50% and 100% of those with ejection fraction … View more

Demographic

Heart Failure